Home

FAQ

1.Where is Tengion headquartered?
2.What year was Tengion incorporated and in what state?
3.On what exchange is Tengion listed and under what stock symbol?
4.How can I purchase shares?
5.When does the fiscal year end?
6.Who is Tengion’s transfer agent?
7.Who are Tengion’s independent auditors?
8.Who is Tengion’s outside legal counsel?
9.Who should I contact if I have any questions?
1.Where is Tengion headquartered?
 Tengion is headquartered in Winston-Salem, North Carolina.

2.What year was Tengion incorporated and in what state?
 Tengion was incorporated in the State of Delaware on July 10, 2003.

3.On what exchange is Tengion listed and under what stock symbol?
 Tengion is traded on the OTC Markets under the symbol TNGN.

4.How can I purchase shares?
 Shares can be purchased through a stockbroker of your choice. Tengion does not have a direct stock purchase plan.

5.When does the fiscal year end?
 December 31

6.Who is Tengion’s transfer agent?
 Tengion's Transfer Agent and Registrar is American Stock Transfer and Trust Company (www.amstock.com; 800-937-5449)

7.Who are Tengion’s independent auditors?
  Ernst and Young
Two Commerce Square
2001 Market Street, Suite 4000
Philadelphia, PA 19103
(215) 448-5000

8.Who is Tengion’s outside legal counsel?
 Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

9.Who should I contact if I have any questions?
 Brian Davis
Chief Financial Officer and Senior Vice President, Finance
ir@tengion.com

Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.05
Change (%)0.00 (0.00%)
Volume127,713
Data as of 09/30/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
September 22, 2014
Tengion Retains Jefferies to Explore Strategic Options for the Company
WINSTON-SALEM, N.C., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that the Company, with the support of its Board of Directors, is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions. "We believe this decision increases our ability to realize the value of our Organ Regene... 
August 13, 2014
Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
WINSTON-SALEM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended June 30, 2014. "Today, we are pleased to announce encouraging six-month interim data for the first five patients implanted in the Phase 1 clinical trial of our Neo-Kidney Augment (NKA) cellular therapy being conducted in Sweden. We believe these early trends support the promising...